Parkinson’s disease, a neurodegenerative disorder that affects millions of people worldwide, poses not only medical challenges, but also increasingly relevant ethical dilemmas. Although research into the causes of this disorder (genetic and environmental) and early diagnosis is progressing, the greatest difficulty continues to be the development of effective treatments that do not compromise the dignity of human life. As an alternative to invasive or limited-efficacy therapies, recent clinical trials with induced pluripotent stem cells (iPS cells) offer a promising avenue for neuronal regeneration, combining the potential of regenerative medicine with strict respect for bioethical principles. This article reviews the latest scientific developments in the management of Parkinson’s disease, highlighting the ethical implications and the emerging prospects for a more human-centered and responsible approach to medicine.

Parkinson’s disease (PD) is a degenerative neurological condition characterized by the gradual onset of hand tremors, balance and coordination problems, stiffness of the arms, legs, and trunk, and slowness of movement. Symptoms worsen over time, and difficulties with chewing, swallowing, talking, walking, and occasionally sleep, depression, or other related problems appear. Its incidence is 1%-2% of the population, affecting almost 9 million people worldwide. It is more common in men than in women and its prevalence increases with age, usually from the age of 60, although there are reported cases of young people with an earlier age of onset.

Although its etiology has been extensively studied, it can be very varied. Initially, the most immediate effect is the progressive loss of dopaminergic neurons in a brainstem region of the brain called the “substantia nigra”. This results in a failure to produce enough “dopamine”, a neurotransmitter molecule responsible for facilitating communication between neurons in different parts of the brain. This neurotransmitter is involved in movement, memory, pleasure, motivation, the brain reward system and learning, and affects other functions outside the brain, such as gastrointestinal motility, blood pressure, and even the activity of the immune system.

Analysis of the root causes of dopaminergic tissue loss is complex, as it may be the result of largely unknown genetic or non-genetic factors. In fact, in most cases, it does not seem to be hereditary, having been associated with environmental effects due to exposure to chemicals, pesticides, or other agents.

In light of the above, it seems clear that to address the problem of disease progression in PD, the factors that trigger the loss of dopamine-producing cells must be identified and efforts made to restore them. The administration of dopamine to patients is a solution that can help alleviate symptoms, but entails temporary reliance.

Genes or other causes related to Parkinson’s disease

Most people affected by PD do not have family members with the condition, suggesting that its etiology is not necessarily genetic. However, there are cases in which there is a family history and also others in which several members of the same family have the disease, which is especially common when Parkinson’s appears at an earlier age, generally under 50 years old. In these cases, researchers have identified different genes that can be inherited in a dominant or recessive pattern.

In dominant patterns of inheritance, the presence of a single allele of the causative gene out of the two present in each individual (paternal and maternal) is sufficient for the disease to manifest. This occurs both in the heterozygous (Aa) and in the more rare homozygous form (AA). In the case of this type of allele, the affected individual will have inherited it from one of their parents who, therefore, would also have developed the disease. Conducting a genealogical study of the family history would support the diagnosis. In the hypothetical case of both parents being heterozygous, the probability of the children having the disease would be ¾ (¼ AA + ½ Aa) while the probability of not having it would be the remaining ¼ (aa). When one of the parents is heterozygous and has the pathology (Aa) and the other is not (aa), half of the children could develop the disease.

When the gene causing PD is recessive, the presence of both alleles (paternal and maternal) is necessary for the disease to manifest. i.e., it only manifests in recessive homozygosity (aa). In this case, when both parents are heterozygous (Aa) neither of them would have the disease, as the recessive allele is masked, but both would be carriers of this allele and ¼ of the children could develop it. In this case, the probability that the children will not have the disease is ¾ (¼ AA + ½ Aa) while that of having it is the remaining ¼ (aa).

In 1997, a heritability study in a large family in a small town in southern Italy, in which PD was passed down from parents to children, discovered an autosomal dominant (AD) gene implicated in the disease(1). This gene responsible for the condition was named SNCA and encodes a protein called alpha-synuclein. It is an abundant protein in the presynaptic terminals of brain neurons. Post-mortem analyses of the brains of people with PD found small accumulations of these proteins, forming what are known as Lewy bodies. However, it has been shown that individuals with PD, even the non-hereditary type, also show large amounts of alpha-synuclein in the Lewy bodies, indicating that this molecule plays an important role in all types of PD.

After several studies, at least nine different major genes involved in PD have been identified, five dominant and four recessive, with the characteristics shown in the Table (Data from the OMIM database). The name PARK followed by a number refers to its relationship with PD, but these are different genes, although with similar effects. All the genes discovered so far are located on autosomes, non-sex chromosomes (AD or AR). While there may be other genes, these are the only ones that have been identified to date(2, 3, 4). Regardless of the cause and although the symptoms are always the same, there is variability in terms of penetrance and the age of onset, which is typically earlier in cases of homozygosity for recessive genes (AR) than for dominant ones (AD). Further information about how each of these genes functions, what we know about their modes of action, family cases in which they have been studied, etc., can be found in the OMIM database (Online Mendelian Inheritance in Man). This database is a comprehensive reference tool containing information on human genes, and has been maintained for decades by the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland (U.S.).

Genome-wide association studies, or GWAS, are also underway. This is an approach that consists of comparing the sequences of common or differential DNA markers across the complete genomes of thousands of people whose individual genome is known and recorded in databases. Thus, apart from the major genes specified, GWAS have been able to identify genetic variants that also contribute to PD, indicating the genetic complexity of this disease. It is believed that there are many minor genes and environmental factors that determine who might develop the disease, when they will develop it, and how it will affect them.

Due to environmental factors or interactions with the rest of the genome, it can happen that some people from the same family who inherit one of the genes involved develop the disease while others live their entire lives without presenting symptoms. There is a lot of research on genes and the environment to try to understand how all the genetic and non-genetic factors interact, but on the whole, there is still much to learn.

Detection and diagnosis of Parkinson’s disease

A search conducted on Medline Plus states that there is no specific laboratory or imaging test that can diagnose PD until the first symptoms appear, so it can be difficult to identify. The first step upon onset of initial symptoms is to conduct a study of the patient’s medical and family history, and a neurological examination to diagnose it. Some tests, such as brain magnetic resonance imaging (MRI), dopamine active transporter scan (DaTSCAN), or blood tests, can help support the diagnosis of PD or rule out other conditions with similar symptoms.

DaTSCAN is a test approved by the U.S. Food and Drug Administration (FDA) in 2011. It is an imaging technique used to visualize the dopamine system in the brain. It is similar to an MRI, but instead of looking at the brain structure, it examines its function. DaTSCAN can view the dopamine levels in the area of the brain involved in controlling movement. The image is analyzed using a radioactive tracer whose presence is measured using a computed tomography scanner (SPECT). The SPECT scanner measures the levels and location of the tracer in the brain. A positive DaTSCAN can differentiate PD from other disorders in which dopamine is not involved. Even so, a positive result does not differentiate PD from other forms of atypical parkinsonism.

Therapeutic and ethical aspects

The initial treatment of PD consists of compensating for the loss of dopamine by administering a precursor to this molecule, L-Dopa (levodopa), usually together with another drug (carbidopa) to facilitate its arrival in the brain. Unfortunately, treatments that base their action on the correction of brain dopamine levels only provide temporary relief from the initial symptoms and do not halt disease progression.

Surgery and deep brain stimulation (DBS) can help in severe cases. In DBS, electrodes surgically implanted in the brain send electrical pulses to stimulate the parts of the brain that control movement. However, it is an invasive method with less than satisfactory results.

Consequently, investigators are exploring novel therapeutic approaches aimed at preventing or reversing cell death, an area which for years has been the focus of efforts to address the challenges posed by degenerative diseases through the application of stem cells(5). Since it was first implemented in regenerative medicine, attempts have been made to apply this methodology in PD, yielding mixed results from both a medical and ethical perspective.

The findings of a clinical trial aimed at the regeneration of dopaminergic tissue with induced pluripotent stem cells – known as iPS cells – have recently been published in Nature(6). The objective was to utilize the method developed by Shinya Yamanaka between 2006 and 2007 to induce the production of iPS cells, which are comparable to embryonic stem cells, but are not sourced from non-implanted human embryos from in vitro fertilization techniques. The method, initially applied in mice and then in humans, consists of modifying somatic cells, skin fibroblasts or others, by means of genetic reprogramming to induce the expression of four genes: Oct3/4, Sox2, c-Myc and Klf4, which are silenced in adult cells(7). Japanese researcher Shinya Yamanaka and British developmental biologist John Gurdon received the 2012 Nobel Prize in Medicine for this contribution. The decision to award the prize to these two scientists took into account that this technological innovation opened a new pathway for the treatment of degenerative diseases without destroying human embryos.

In fact, interest in the use of iPS cells in reparative medicine is growing worldwide. There are currently more than 100 clinical trials registered in the ClinicalTrials.gov database, mainly seeking to repair damaged tissues that cause degenerative diseases, such as eye diseases, cancer, and neurological diseases.

Last month, a team of Japanese researchers reported the results of the application of this technology in a phase I/II clinical trial conducted at Kyoto University Hospital(6). Seven patients (aged 50 to 69 years) received bilateral transplantation of iPS-cell derived dopaminergic cells. The primary outcomes were safety and adverse events, but the study also examined the effects of transplantation on motor symptoms and dopamine production for 24 months. The results were very promising, as there were no serious adverse events (only mild to moderate events) and the MRI showed no graft overgrowth or tumor formation. Most patients improved their score on the Unified Parkinson’s Disease Rating Scale. This trial demonstrated that dopaminergic cells derived from iPS cells survive, produce dopamine, and do not form tumors, thus supporting their safety and potential clinical benefits in the treatment of PD.

Following this and other parallel trials currently underway in different institutions, it is reasonable to suggest that the prospects are very positive, both in terms of safety and what it represents as a technology that respects life. The iPS cells can be derived from the patient’s own tissues, thereby avoiding the potential issue of immune rejection due to the different histocompatibility profile presented by embryonic stem cells. As a result, the application of iPS cells is superseding other attempts to apply reparative medicine using embryonic stem cells, which could yield equally positive results from a medical point of view, but which are based on the use of embryonic or fetal tissue. It should be remembered that embryos (from fertilization to week 8) and fetuses (from week 9 to delivery) are the initial and most critical stages of human life, and that, as stated in the Code of Medical Ethics of the Spanish Medical Colleges Organization: “The human being is an end in himself throughout all stages of the biological cycle, from conception to death. The physician is bound, in all of their actions, to safeguard the dignity and integrity of the persons under their care.”

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

 

References

[1] Spillantini, M., Schmidt, M., Lee, VY. et al. α-Synuclein in Lewy bodies. Nature, 1997; 388:839–840.

[2] Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet. 2023; 68(3):125-130.

[3] Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012; Jan;2(1):a008888.

[4] Savitt, J.M., Dawson, V.L., Dawson, T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. The Journal of clinical investigation, 2006; 116(7):1744-1754.

[5] Jouve, N. Las células madre. Alquimia celular para una nueva Medicina. Digital Reasons, Madrid, 2023.

[6] Sawamoto, N., Doi, D., Nakanishi, E. et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature.2025; https://doi.org/10.1038/s41586-025-08700-0

[7] Takahashi, K., Tanabe, K, Yamanaka, Set al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell.  2007; 30; 131(5): 861-872.

Share This Story, Choose Your Platform!